Recent Developments: As of mid-2026, the FDA has proposed to exclude popular GLP-1 substances like Semaglutide, Tirzepatide, and Liraglutide from the list, concluding that there is no clinical need to compound them from bulk ingredients when approved versions are available
Investigations are still underway to determine if Rybelsus or another GLP-1 caused or contributed to these conditions and deaths
Despite a significant improvement in the treatment of T2D and CVD over the past few decades, reducing CVD in patients with T2D solely with an optimal glycemic control has been challenging [2]
While both forms can be used as a supplement, ALCAR is often preferred due to its ability to cross the blood-brain barrier allowing it to interact with nerves in the brain, and also donate its acetyl molecule, a key step in neurotransmitter formation, required for healthy brain activity
Now, in a pair of clinical trials, researchers investigated whether tirzepatide could improve symptoms of obstructive sleep apnea (OSA), a condition in which individuals may stop breathing while they sleep